Business Description
Theseus Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
Description
Theseus Pharmaceuticals Inc is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. The company's development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 53.32 | |||||
| Equity-to-Asset | 0.96 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.11 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 0 | |||||
| Beneish M-Score | 0 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.88 | |||||
| 9-Day RSI | 30.92 | |||||
| 14-Day RSI | 34.28 | |||||
| 6-1 Month Momentum % | -40.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 43.66 | |||||
| Quick Ratio | 43.66 | |||||
| Cash Ratio | 43.14 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -30.83 | |||||
| ROA % | -20.38 | |||||
| ROIC % | -470.67 | |||||
| ROC (Joel Greenblatt) % | -1191.13 | |||||
| ROCE % | -21.2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.96 | |||||
| Price-to-Tangible-Book | 0.98 | |||||
| EV-to-EBIT | 1.66 | |||||
| EV-to-EBITDA | 1.66 | |||||
| EV-to-FCF | -0.5 | |||||
| Price-to-Net-Current-Asset-Value | 1.03 | |||||
| Price-to-Net-Cash | 1.04 | |||||
| Earnings Yield (Greenblatt) % | 51.04 |
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:THRX
Executives
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0 | ||
| EPS (TTM) ($) | -1.016 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 34.28 | ||
| 14-Day ATR ($) | 0.7277 | ||
| 20-Day SMA ($) | 6.707 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range ($) | 4.857 - 24.54 | ||
| Shares Outstanding (Mil) | 38.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Theseus Pharmaceuticals Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Theseus Pharmaceuticals Inc Analysis
Share your researchHeadlines
See More
No news.